Study of Filovirus Disease Morbi-mortality

Condition(s) studied

Study summary

Filoviruses, including Ebola and Marburg, cause hemorrhagic fevers associated with high mortality and still limited scientific literature, in particular for some rare species such as the Bundibugyo virus. The current epidemic of Bundibugyo virus disease in the Democratic Republic of the Congo (DRC) and Uganda, which has been declared a public health emergency of international concern by the World Health Organization (WHO), illustrates the importance of better characterizing this infection, whose genetic specificities complicate the transposition of diagnostic, therapeutic and vaccine tools developed for Ebola Zaire.

Given the incubation time of filoviruses and international mobility, cases can be diagnosed and managed outside of epidemic areas, including in exposed caregivers. However, clinical, biological and therapeutic knowledge available in this context remain very limited.

This situation justifies the implementation of an observational cohort of patients with a confirmed filovirus disease, who have arrived or were diagnosed in France.

This cohort will describe the clinical evolution of the disease, its prognosis and its pathophysiology, as well as identify new diagnostic, therapeutic or preventive leads.

Eligibility

Primary outcome measure(s)

• Vital status on day 28. — 28 days
  The objective is to describe mortality at day 28 in patients with confirmed filovirus diseases. Day 1 is the day of the first documented positive PCR, regardless of the location of the PCR.

Trial sites (1)

More Assistance Publique - Hôpitaux de Paris trials in France